watching it I think it can get to $100. I tried all night to post it without luck. It is under webcasts at NWBO webpage.
Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics' lead product, EksoTM, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.
About Ekso Bionics
Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable
The release of this study comes on the heels of four centers in Germany recently ordering the Ekso robotic exoskeleton and after utilizing the Ekso GT and other competitors' devices with their patients. BG Bergmannstrost, BG Tubingen, BG Duisburg and RKU Ulm have all recently placed orders of the Ekso Bionics suit and the centers will use the Ekso GT robotic exoskeleton to perform gait training. The device uniquely offers gait training rehabilitation for complete SCI, incomplete SCI and non-or pre-ambulatory individuals post-stroke stroke patients using variable assistance and a hemiplegic mode that does not otherwise exist in the industry.
"Germany is the ideal market for us, because the doctors take the time to compare systems by actually using them with their own patients. They don't just watch a demonstration of an optimized pilot operating the systems. They try different patients of different sizes and conditions. In that environment, there is no match at this time," said Ekso Bionics Chief Executive Officer Nathan Harding. "Rehab is where the market is right now, and our exoskeleton offering is unparalleled in terms of ease-of-use and patient inclusion - this is one of the biggest reasons behind the recent additional uptake and shipment of 15 systems during the last quarter," he added
will take this above $25
in 2013 and lower year over year sales in 2014. Clearly, EKSO is going higher.
last year and lower year over year so far in 2014. EKSO CLEARLY going higher.
The offering, composed of two $650 million tranches — one a five-year due in 2019 and the other a seven-year due in 2021 — marks the company’s first debt offering. It will be up to Twitter’s discretion when and whether to convert the notes into cash, stock or a combination of both, at a conversion rate that will be determined upon pricing.
The convertible debt offering comes a bit more than two months after Twitter tapped the former Goldman Sachs banker who led its IPO, Anthony Noto, to serve as its chief financial officer.
Twitter stayed mum on what it intends to do with the proceeds, beyond paying for the cost of hedging the transactions to minimize the dilution of common shareholders, earmarking the funds only for “general corporate purposes.
Shares of Twitter, which gained 4.5% Wednesday, fell 1.5% in after-hours trading on news of the capital raise.
Another high-flying, high-multiple company that has utilized convertible bonds to raise capital recently is Tesla Motors TSLA +0.95%, which sold debt in May 2013and February of this year.
For the companies’ purposes, debt is cheap at today’s interest rates and if everything goes according to plan there will be plenty of money to either pay the interest or buy out the bondholders rather than a dilutive conversion into common equity.